Mean platelet volume and cardiovascular outcomes in patients with coronary heart disease: A meta-analysis of prospective studies

BACKGROUND: While there is evidence suggesting that increased mean platelet volume (MPV) is linked to adverse cardiac outcomes in patients with acute coronary syndrome, the association between MPV and clinical outcomes in patients with coronary heart disease (CHD) remains a topic of debate. This meta-analysis focuses on comprehensively reviewing existing research regarding the association between MPV levels and the prognosis of patients with CHD. METHODS: We included all relevant prospective studies carried out before January 31, 2024. The cutoff values, which also defined high/low-MPV levels, had transformed continuous variables into a dichotomous variables. The results of these studies reported hazard ratios (HRs) for all-cause mortality or incidence of major adverse cardiac events (MACEs). RESULTS: A total of 10 prospective studies, including 11,647 patients with CHD, were enrolled in this meta-analysis. The pooled HR for long-term all-cause mortality was 1.06 (95% confidence interval [CI], 0.89-1.27), with no statistically significant association between increased MPV and long-term all-cause mortality in patients with CHD. Increased MPV level was associated with a significantly increased risk of short-term all-cause mortality (HR, 2.10 [95% CI, 1.34-3.29]; P < .05). For the incidence of long-term MACEs, the pooled HR for long-term MACE occurrence was 1.14 (95% CI, 1.02-1.28), showing a statistically significant correlation with increased MPV in patients with CHD. CONCLUSION: This present meta-analysis showed that an increased MPV was associated with an increased risk of short-term all-cause mortality and long-term MACEs in patients with CHD. No association was found between elevated MPV levels and the incidence of long-term mortality in patients with CHD.